Popular filter options for alopecia areata trials
Phase 3 Alopecia Areata Clinical Trials
View 44 phase 3 alopecia areata medical studies.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
JAK Inhibitor
CTP-543 for Alopecia Areata
“ I have been only able to use holistic and over the counter. I have suffered from hair loss since middle school. I would give anything to find something that works. It really affects your quality of life.”
Alopecia Areata Clinical Trials With No Placebo
View 44 alopecia areata medical studies that do not have a placebo group.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Cellular Regenerative Treatment
Biocellular-Cellular Regenerative Treatment for Alopecia and Scarring Alopecia
“ I have tried steroid injections. Topical clobetasol. Used my laser for 2 years. Just about a month ago started oral minoxidil.”
Janus Kinase (JAK) Inhibitor
Ruxolitinib for APECED-Associated Alopecia Areata
“ I have tried Xeljanz a few years back and it worked. I could not afford the copay’s and all the hair fell out. I want to see if there is a way I can be active in helping to find a cure.”
View More Alopecia Areata Trials
See another 19 many medical studies focused on alopecia areata.
Frequently Asked Questions
Introduction to alopecia areata
What are the top hospitals conducting alopecia areata research?
When it comes to advancements in the field of alopecia areata research, several top hospitals across the United States are making significant strides. In Tampa, ForCare Clinical Research is actively involved in five clinical trials focused on this condition, with a total of eight trials conducted thus far. Notably, their first recorded trial took place in 2018. Meanwhile, the Icahn School of Medicine at Mount Sinai in New York has also been dedicated to studying alopecian New York has also been dedicated to studying alopecia areata and currently has five ongoing trials in progress. With a history of 15 completed trials since their first one in 2015, they have become an important center for advancing our understanding of this hair loss disorder.
In Indianapolis, Dawes Fretzin Clinical Research Group is contributing to alopecia areata research through four active clinical trials and a total count of ten previous studies. They joined forces with patients as early as 2016 to begin investigating potential treatments for this condition. Investigate MD located in Scottsdale may have fewer active clinical trials - three currently - but they too play an essential role by building upon the knowledge gained from their four previously conducted alopecia areata investigations since recording their initial trial just two years ago.
Lastly but certainly not least important is DS Research situated within Louisville; despite having three active projects related specifically towards Alopecia Areata which helps them make invaluable contributions into bettering treatment pathways available against such conditions through conducting prior experiments summing up tilldate so far counting upto about five studies beginning most lately only during2018.
These hospitals represent beacons of hope for those affected by alopecia areata—a condition characterized by sudden hair loss—and demonstrate the dedication and commitment among medical professionals nationwide who strive to find effective treatments and potential cures. Through these collaborative efforts across various locations throughout America's healthcare landscape emerges confidence that every study undertaken brings us closer towards combating this challenging disorder more effectively while providing much-needed relief for individuals living with alopecia areata.
Which are the best cities for alopecia areata clinical trials?
When it comes to alopecia areata clinical trials, several cities emerge as frontrunners in research and development. Portland, Oregon leads the pack with 12 active trials investigating treatments like Baricitinib, Deucravacitinib Dose 1, and CTP-543. Minneapolis, Minnesota closely follows with 11 ongoing studies focused on innovative approaches such as PF-06651600, Baricitinib, and Farudodstat. San Antonio, Texas also boasts 11 active trials examining treatment options like CTP-543, Deucravacitinib Dose 1, and Daxdilimab. New Haven in Connecticut, Minnesota closely follows with 11 ongoing studies focused on innovative approaches such as PF-06651600, Baricitinib, and Farudodstat. San Antonio, Texas also boasts 11 active trials examining treatment options like CTP-543, Deucravacitinib Dose 1, and Daxdilimab. New Haven in Connecticut hosts 10 active trials exploring interventions including Deucravacitinib Dose 1,P F-06651600,and Baricitinib.Other notable city is Tampa Florida where there are currently9active Trials studyingDeucravacitinibDose 1 ,BaricitiniandCTP/543.These cities provide individuals dealing with alopecia areata access to cutting-edge clinical trials that pave the way for advancements in care and bring hope for better treatment outcomes
Which are the top treatments for alopecia areata being explored in clinical trials?
Exciting advancements in the field of alopecia areata have led to the exploration of several cutting-edge treatments in clinical trials. PF-06651600, with three active trials and four all-time alopeciar all-time alopecia areata trials since its introduction in 2016, stands out as a promising option. Additionally, baricitinib and dupilumab show great potential, each undergoing two active trials while accumulating three all-time alopecia areata trials since being listed in 2018. An upcoming treatment called farudodstat is also making waves with one ongoing trial and being introduced for the first time in 2023. These innovative therapies offer hope for individuals suffering from alopecia areata by potentially providing effective solutions for this challenging condition.
What are the most recent clinical trials for alopecia areata?
Exciting advancements are being made in the field of alopecia areata treatment, with recent clinical trials showcasing promising potential for patients. Among these trials is ADX-914, an experimental drug currently in Phase 2. Additionally, farudodstat, dupilumab, oral minoxidil, and TDM-105795 topical solution have also shown positive results in Phase 2 studies. These developments offer hope to individuals suffering from alopecia areata and may pave the way for more effective treatments in the future.
What alopecia areata clinical trials were recently completed?
Exciting developments have recently emerged in the field of alopecia areata, with several clinical trials achieving completion and offering potential solutions for those affected by this autoimmune condition. In April 2022, LEO Pharma successfully concluded a trial exploring the efficacy of Delgocitinib cream. Technoderma Medicines Inc., on the other hand, completed two separate trials involving TDM-105795 in February 2022 and April 2021 respectively. Concert Pharmaceuticals' CTP-543 trial reached its endpoint in February 2021, while Pfizer's investigation into Etrasimod wrapped up in July 2020. Additionally, the University of Arizona conducted a trial examining Keratinocyte growth factor which concluded its study phase back in April 2020. These recent advancements highlight ongoing efforts to find effective treatments for alopeciaf Arizona conducted a trial examining Keratinocyte growth factor which concluded its study phase back in April 2020. These recent advancements highlight ongoing efforts to find effective treatments for alopecia areata and offer hope to individuals grappling with hair loss caused by this challenging condition.